Romanelli Roberta Maia de Castro, Anchieta Lêni Márcia, Bueno E Silva Ana Carolina, de Jesus Lenize Adriana, Rosado Viviane, Clemente Wanessa Trindade
Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, MG, Brazil; Universidade José do Rosário Vellano, Faculdade de Ciências Médicas, Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, MG, Brazil; Universidade Federal de Minas Gerais (UFMG), Hospital das Clínicas, Unidade Neonatal de Cuidados Progressivos, Belo Horizonte, MG, Brazil.
J Pediatr (Rio J). 2016 Sep-Oct;92(5):472-8. doi: 10.1016/j.jped.2016.01.008. Epub 2016 Apr 22.
The aim of this study was to compare two different empiric treatments for late-onset neonatal sepsis, vancomycin and oxacillin, in a neonatal intensive care unit with a high prevalence of coagulase-negative Staphylococcus.
A cross-sectional study was conducted in an neonatal intensive care unit from 2011 to 2014. Data from the medical records of at-risk newborns were collected daily. Infections were defined according to the National Health Surveillance Agency criteria. Data analysis was performed using an internal program.
There was a significant reduction in the number of Staphylococcus aureus infections (p=0.008), without endocarditis, meningitis, or lower respiratory tract infection, as well as a reduction in the frequency of deaths related to S. aureus infection. There were no significant changes in the incidence of Gram-negative bacterial or fungal infections. An increase in coagulase-negative Staphylococcus infections was observed (p=0.022). However, there was no measured increase in related morbidity and mortality. There was a reduction in the median number of days of treatment with oxacillin from 11.5 to 6 days (p<0.001) and an increase of one day in the median number of days of treatment with vancomycin (p=0.046).
Modification of the empiric treatment regimen for neonatal late-onset sepsis with use of oxacillin showed a significant reduction in S. aureus infections, as well as a reduction in the frequency of infections with major organ system involvement and mortality due to infection with this microorganism. As a result, oxacillin can be considered as an effective treatment for late-onset sepsis, making it possible to avoid broad-spectrum antibiotics.
本研究旨在比较万古霉素和苯唑西林这两种针对晚发型新生儿败血症的不同经验性治疗方法,该研究在凝固酶阴性葡萄球菌感染率较高的新生儿重症监护病房中进行。
于2011年至2014年在一家新生儿重症监护病房开展了一项横断面研究。每天收集高危新生儿病历中的数据。感染根据国家卫生监督机构的标准进行定义。使用内部程序进行数据分析。
金黄色葡萄球菌感染数量显著减少(p = 0.008),且无感染性心内膜炎、脑膜炎或下呼吸道感染,同时与金黄色葡萄球菌感染相关的死亡频率也有所降低。革兰氏阴性菌或真菌感染的发生率无显著变化。观察到凝固酶阴性葡萄球菌感染有所增加(p = 0.022)。然而,相关的发病率和死亡率并未出现可测的增加。苯唑西林治疗的中位天数从11.5天减少至6天(p < 0.001),万古霉素治疗的中位天数增加了1天(p = 0.046)。
使用苯唑西林对新生儿晚发型败血症的经验性治疗方案进行调整后,金黄色葡萄球菌感染显著减少,同时累及主要器官系统的感染频率以及该微生物感染所致的死亡率也有所降低。因此,苯唑西林可被视为治疗晚发型败血症的有效药物,从而有可能避免使用广谱抗生素。